Myriam Chalabi Discusses Neoadjuvant Immunotherapy and NEOASIS Study Findings at AACR25 – Agenus

Agenus shared a post on LinkedIn:

“Yesterday at AACR25, Dr. Myriam Chalabi participated in the session ‘Neoadjuvant Treatment Across Tumor Types: One Size Does Not Fit All,’ where she discussed the evolving neoadjuvant landscape and the promising role of immunotherapy—including clinical studies evaluating botensilimab and balstilimab.

Learn more and view her NEOASIS study presentation.”